热门资讯> 正文
Sagimet Biosciences宣布与Teva Pharmaceutical子公司达成许可协议
2025-12-17 20:06
- License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications
- Collaboration supports Sagimet's fixed-dose combination (FDC) program currently in clinical development
- Sagimet's Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025
- Sagimet anticipates selecting one of the innovative forms of resmetirom licensed from TAPI for combination with denifanstat in a fixed dose combination (FDC) tablet for use in Phase 3
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。